On the public citation graph
Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease
0 signed · 76 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jamanetworkopen.2022.6567openalex-snapshot
Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents
inferredcites →https://doi.org/10.1001/jamaneurol.2019.3988openalex-snapshot
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
inferredcites →https://doi.org/10.1002/anie.201706376openalex-snapshot
A Computational Method for Unveiling the Target Promiscuity of Pharmacologically Active Compounds
inferredcites →https://doi.org/10.1002/cmdc.201900097openalex-snapshot
Design of Natural‐Product‐Inspired Multitarget Ligands by Machine Learning
inferredcites →https://doi.org/10.1002/cpt.37openalex-snapshot
Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective
inferredcites →https://doi.org/10.1002/jps.23266openalex-snapshot
Development of a Physiologically Based Pharmacokinetic Model for the Rat Central Nervous System and Determination of an In Vitro–In Vivo Scaling Methodology for the Blood–Brain Barrier Permeability of Two Transporter Substrates, Morphine and Oxycodone
inferredcites →https://doi.org/10.1002/med.20164openalex-snapshot
How druggable is protein kinase CK2?
inferredcites →https://doi.org/10.1002/minf.201200141openalex-snapshot
Chemically Advanced Template Search (CATS) for Scaffold‐Hopping and Prospective Target Prediction for ‘Orphan’ Molecules
inferredcites →https://doi.org/10.1002/open.201900222openalex-snapshot
Synthetic Activators of Cell Migration Designed by Constructive Machine Learning
inferredcites →https://doi.org/10.1002/qsar.200330825openalex-snapshot
Collection of Bioactive Reference Compounds for Focused Library Design
inferredcites →https://doi.org/10.1002/trc2.12095openalex-snapshot
Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
inferredcites →https://doi.org/10.1002/trc2.12445openalex-snapshot
Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease
inferredcites →https://doi.org/10.1006/bbrc.1994.1972openalex-snapshot
Cloning of a Novel Putative Protein Kinase Having a Leucine Zipper Domain from Human Brain
inferredcites →https://doi.org/10.1007/978-0-387-84858-7openalex-snapshot
The Elements of Statistical Learning: Data Mining, Inference, and Prediction
inferredcites →https://doi.org/10.1007/978-3-540-78246-9_38openalex-snapshot
KNIME: The Konstanz Information Miner
inferredcites →https://doi.org/10.1007/s00415-020-09866-5openalex-snapshot
CNS penetration of potential anti-COVID-19 drugs
inferredcites →https://doi.org/10.1007/s10928-007-9053-5openalex-snapshot
Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs
inferredcites →https://doi.org/10.1016/j.drudis.2012.05.001openalex-snapshot
Translational CNS medicines research
inferredcites →https://doi.org/10.1016/j.drudis.2018.05.010openalex-snapshot
Machine learning in chemoinformatics and drug discovery
inferredcites →https://doi.org/10.1016/j.jsps.2016.07.002openalex-snapshot
An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice
inferredcites →https://doi.org/10.1016/s0014-4886(03)00042-6openalex-snapshot
Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer’s disease brains examined by in situ hybridization
inferredcites →https://doi.org/10.1016/s0021-9258(17)41790-xopenalex-snapshot
Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine 39 as the primary phosphate acceptor.
inferredcites →https://doi.org/10.1016/s0140-6736(18)31116-4openalex-snapshot
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
inferredcites →https://doi.org/10.1016/s0140-6736(20)30304-4openalex-snapshot
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
inferredcites →https://doi.org/10.1016/s1474-4422(15)70016-5openalex-snapshot
Neuroinflammation in Alzheimer's disease
inferredcites →https://doi.org/10.1021/acs.chemrestox.0c00307openalex-snapshot
Development of a Web-Based Toolbox to Support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within Nonanimal Testing Strategies
inferredcites →https://doi.org/10.1021/acs.jmedchem.7b00843openalex-snapshot
Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer’s Disease
inferredcites →https://doi.org/10.1021/ci00057a005openalex-snapshot
SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules
inferredcites →https://doi.org/10.1021/jm401411zopenalex-snapshot
Molecular Similarity in Medicinal Chemistry
inferredcites →https://doi.org/10.1021/jm401490popenalex-snapshot
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
inferredcites →https://doi.org/10.1021/jm5013984openalex-snapshot
Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models
inferredcites →https://doi.org/10.1023/a:1007017116171openalex-snapshot
Evaluation of the Uncertainty in an Oral Reference Dose for Methylmercury Due to Interindividual Variability in Pharmacokinetics
inferredcites →https://doi.org/10.1038/nrd1132openalex-snapshot
Targeting JNK for therapeutic benefit: from junk to gold?
inferredcites →https://doi.org/10.1038/nrm906openalex-snapshot
Mixed-lineage kinase control of JNK and p38 MAPK pathways
inferredcites →https://doi.org/10.1038/s41467-021-21330-0openalex-snapshot
Machine learning identifies candidates for drug repurposing in Alzheimer’s disease
inferredcites →https://doi.org/10.1038/s41598-022-11879-1openalex-snapshot
Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection
inferredcites →https://doi.org/10.1042/bj20021469openalex-snapshot
Protein kinase CK2: structure, regulation and role in cellular decisions of life and death
inferredcites →https://doi.org/10.1056/nejmoa1706441openalex-snapshot
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
inferredcites →https://doi.org/10.1056/nejmoa1812840openalex-snapshot
Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
inferredcites →https://doi.org/10.1083/jcb.201103153openalex-snapshot
DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity
inferredcites →https://doi.org/10.1093/toxsci/54.1.71openalex-snapshot
Sensitivity Analysis of a Physiological Model for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD): Assessing the Impact of Specific Model Parameters on Sequestration in Liver and Fat in the Rat
inferredcites →https://doi.org/10.1111/cts.12486openalex-snapshot
Prediction of Transporter‐Mediated Drug‐Drug Interactions for Baricitinib
inferredcites →https://doi.org/10.1111/j.1539-6924.1994.tb00241.xopenalex-snapshot
Incorporation of Pharmacokinetics in Noncancer Risk Assessment: Example with Chloropentafluorobenzene
inferredcites →https://doi.org/10.1124/dmd.119.089235openalex-snapshot
Comparative Proteomics Analysis of Human Liver Microsomes and S9 Fractions
inferredcites →https://doi.org/10.1126/scitranslmed.aaz4699openalex-snapshot
Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss
inferredcites →https://doi.org/10.1186/s12974-019-1565-6openalex-snapshot
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro
inferredcites →https://doi.org/10.1186/s13075-019-1964-1openalex-snapshot
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
inferredcites →https://doi.org/10.1186/s13195-020-00614-5openalex-snapshot
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
inferredcites →https://doi.org/10.1208/s12248-013-9496-0openalex-snapshot
Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach
inferredcites →https://doi.org/10.1602/neurorx.2.4.554openalex-snapshot
Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
inferredcites →https://doi.org/10.2174/138161207780858384openalex-snapshot
JNK Signalling: A Possible Target to Prevent Neurodegeneration
inferredcites →https://doi.org/10.3389/fphar.2015.00321openalex-snapshot
c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease
inferredcites →https://doi.org/10.3390/ph10010007openalex-snapshot
CK2—An Emerging Target for Neurological and Psychiatric Disorders
inferredcites →https://doi.org/10.3390/ph14070680openalex-snapshot
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
inferredcites →https://doi.org/10.4155/fmc-2019-0163openalex-snapshot
An Overview of Glutaminyl Cyclase Inhibitors for Alzheimer’s Disease
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1007/s10787-025-01796-wopenalex-snapshot
Targeting the JAK/STAT3/SOCS signaling pathway in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s12017-025-08898-2openalex-snapshot
Targeting Microglial Activation to Modulate Neuroinflammation in Alzheimer’s Disease
inferred← citeshttps://doi.org/10.1016/j.cmpb.2025.108604openalex-snapshot
Drug repurposing using artificial intelligence, molecular docking, and hybrid approaches: A comprehensive review in general diseases vs Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.phrs.2024.107443openalex-snapshot
Microglia-mediated neuron death requires TNF and is exacerbated by mutant Huntingtin
inferred← citeshttps://doi.org/10.1021/acsomega.5c04340openalex-snapshot
Drug Repurposing by Virtual Screening: Identification of New Already Approved ROCK Inhibitors as Promising Drugs to Target Neurodegeneration
inferred← citeshttps://doi.org/10.1038/s44220-025-00460-0openalex-snapshot
Proteogenomic signature of Alzheimer’s disease and related dementia risk in individuals with major depressive disorder
inferred← citeshttps://doi.org/10.1080/17568919.2026.2714022openalex-snapshot
Rational drug design for Alzheimer’s disease: from approved therapies to next-generation clinical candidates and AI-guided innovation
inferred← citeshttps://doi.org/10.1101/2024.09.11.24313493openalex-snapshot
Proteogenomic signature of risk of Alzheimer’s disease and related dementia risk in individuals with a history of major depression disorder
inferred← citeshttps://doi.org/10.1146/annurev-pharmtox-062124-043519openalex-snapshot
Neuroinflammation and Disease: Pathways and Opportunities
inferred← citeshttps://doi.org/10.1186/s13064-026-00290-5openalex-snapshot
Current and emerging therapeutic approaches in Alzheimer’s disease
inferred← citeshttps://doi.org/10.12680/balneo.2026.1024openalex-snapshot
Early-stage research and new pharmacological targets in Alzhei-mer's dementia
inferred← citeshttps://doi.org/10.1515/biol-2022-1051openalex-snapshot
Neurodegenerative diseases and neuroinflammation-induced apoptosis
inferred← citeshttps://doi.org/10.3389/fnagi.2026.1818660openalex-snapshot
Anti-inflammatory and immunomodulatory therapies are associated with reduced risk of age-associated neurodegenerative diseases: impact of sex and treatment duration
inferred← citeshttps://doi.org/10.3389/fnagi.2026.1880374openalex-snapshot
JAK/STAT signaling pathway inhibitors in neurodegenerative diseases: current status and future perspectives
inferred← citeshttps://doi.org/10.3389/fnmol.2024.1441691openalex-snapshot
Common cytokine receptor gamma chain family cytokines activate MAPK, PI3K, and JAK/STAT pathways in microglia to influence Alzheimer’s Disease
inferred← citeshttps://doi.org/10.3390/biology14101433openalex-snapshot
From Genome-Wide SNPs to Neuroimmune Crosstalk: Mapping the Genetic Landscape of IBD and Its Brain Overlap
inferred← citeshttps://doi.org/10.3390/jcm14020386openalex-snapshot
The Crucial Role of the Blood–Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications
inferred← citeshttps://doi.org/10.64898/2026.03.06.26347446openalex-snapshot
Immunotherapies for risk reduction in age-associated neurodegenerative diseases: impact of sex and treatment duration
showing the first 18 of 19 · page through all 19
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.